BLMH

Across TCGA pan-cancer cohorts, BLMH mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BLMH data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BLMH mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BLMH expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where BLMH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.961	0.691	.003	27	view →
GBM	DFS	Median	All	0.261	0.481	.001	10	view →
PDAC	DFS	Quartile	III,IV	0.368	0.759	.035	5	view →
UCEC	OS	Tertile	All	0.799	0.948	.043	2	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.785	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BLMH–CCRCC (OS)

Open the CCRCC breakdown →